Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

NCT02856451 · clinicaltrials.gov ↗
COMPLETED
Status
486
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bristol-Myers Squibb